agents and cancer-related supportive care drugs have been approved for use by the U.S. Food and Drug Administration (FDA, 2010 ). An estimated 25% of anticancer agents in the research pipeline are designated for oral administration (Michaud & Choi, 2008) . The infrastructure of chemotherapy administration is changing from episodic intravenous (IV) infusions to continuous oral daily dosing. Many inhibitor therapies are cytostatic and are most effective when given daily over pro-longed periods of time, perhaps for the remainder of the patient's life (Weingart et al., 2008) .
With the increase in oral therapies for cancer, concerns about adherence have also increased. Adherence is defined by the World Health Organization (WHO, 2003) as the extent to which a person's behavior in taking medication or executing lifestyle changes agrees with recommendations from a health-care provider. Oncology nurses have been in the forefront of patient education throughout the continuum of cancer care and have recently begun to identify and address the challenges of supporting an increasing number of patients treated with oral agents. Suboptimal adherence may be the greatest barrier to the effective use of new oral agents. Nonadherence can result in drug resistance and suboptimal response to therapy, disease progression, and death. Poor adherence to tamoxifen, for example, has been significantly associated with increased risk of death from breast cancer (Thompson, Dewar, Fahey, & McCowan, 2007) .
History of Oral Therapy Adherence Issues
Primary care practitioners have been aware of adherence issues with prescribed therapies for many years. A search of medical and nursing literature yields numerous articles on HIV, diabetes, and heart failure management citing barriers to optimal adherence and nursing interventions to improve adherence. Patient nonadherence is a greater problem for chronic diseases, such as cancer, than for acute illnesses (Dunbar-Jacob, 2007; Osterberg & Blaschke, 2005) and often reflects the complexity of the regimen rather than willful nonadherence of the patient (Weingart et al., 2007) . Partridge, Avorn, Wang, and Winer (2002) related adherence to sociodemographic characteristics, the regimen (side effects, duration of treatment) and the illness (symptoms, seriousness of diagnosis). Although oncology health-care providers generally assume that patients with cancer will adhere to treatment recommendations because of the gravity of a cancer diagnosis, that premise has not been proven and is reflected in reports of adherence as low as 20% (Partridge et al., 2002) .
Published studies on adherence to oral regimens for cancer illustrate the pervasiveness of nonadherence. In a study of 2,816 Irish women with early-stage breast cancer, nonadherence to adjuvant tamoxifen was reported to be 22% within the first year of treatment and 35% during the third year (Barron, Connolly, Bennett, Feely, & Kennedy, 2007) . In a study of 2,378 U.S. patients prescribed adjuvant tamoxifen therapy for primary breast cancer, adherence during year 1 of treatment was assessed at 87% but declined to 50% after 4 years (Partridge, Wang, Winer, & Avorn, 2003) . Tsang, Rudychev, and Pescatore (2006) analyzed pharmacy claims to determine adherence of 4,043 patients prescribed imatinib over 24 months. Overall adherence was 75%, and only 50% of patients were 100% adherent. In a small study of patients with breast cancer (N = 51), adherence to an oral cyclophosphamide regimen was only 57% (Lebovits et al., 1990 ). Adherence in patients with hematologic malignancies (N = 108) was reported as 27% with prednisone and 17% with allopurinol (Ruddy, Mayer & Partridge, 2009) .
Although advancing age is often regarded as a barrier to optimal adherence, studies have shown that young adults can be nonadherent as well. Nonadherence to prophylactic antibiotic medications among adolescents following bone marrow transplant was studied by Kennard et al. (2004) . Serum assays found that 27% of the patients (n = 44) had no detectable antibiotic drug level, and survival rates measured 6 years later were lower in the group of patients categorized as nonadherent.
Another challenge encountered during cancer therapy is "overadherence," which may involve taking more medication than prescribed or continuing on medication despite a recommendation to interrupt dosing. Patients who are fearful of disease progression or death if they do not take their medicine may push themselves to endure debilitating side effects rather than call the clinic for assistance with dose interruption or modification (Palmieri & Barton, 2007) . A longheld belief that cancer treatment necessarily involves suffering also may keep patients from contacting the nurse for help. When a patient expects to feel poorly during therapy, there is little reason to report side effects.
Many methods to evaluate adherence have been developed and reported in the literature, including direct questioning, pill counts, electronic pill containers, diaries, and telephone dose records (Birner, Bedell, Avery, & Ernstoff, 2006; Moore, 2007; Winkeljohn, 2007) . Despite ongoing reports of adherence issues with oral medications, no "gold standard" method to measure adherence has been established (WHO, 2003) .
Barriers to Adherence
Adherence is a multifaceted phenomenon determined by the interplay of a number of internal and external factors (WHO, 2003) . Adherence to an oral anticancer regimen can be a challenging commitment for patients and their care partners. Highly motivated, capable patients who want an active role in their care are best suited to manage home oral administration of chemotherapy, but with good teaching and support, less motivated patients can also be successful. However, even when patients are motivated to succeed, a number of barriers-many beyond the control of the patient or health-care providermay negatively affect adherence (see Table 1 ).
When an agent is available in both oral and IV formulations and the efficacy is essentially equivalent, the choice may depend on physician and patient preference, comparative sideeffect profiles, insurance coverage, and patient commitment to adhering to the oral regimen. Many clinicians believe that oral drugs have a broader therapeutic index than IV drugs and, therefore, are safer and less toxic. This is not true: the therapeutic index is based on the class of drug and its mechanism of action, not on the route of administration. Therefore, the therapeutic index of oral agents and the IV equivalent is the same (Weingart et al., 2008) . What may be different are specific side effects, and these side effects may alter a patient's preference for a particular drug. An example is IV fluorouracil (5-FU) versus the oral 5-FU prodrug capecitabine (Xeloda). The gastrointestinal side-effect profile of the two drugs is similar, although less severe for the oral form. However, a dermatologic Atkins & Fallowfield, 2006; Haynes, McDonald, & Garg, 2002; Lebovits et al., 1990; Madden et al., 2008; Michaud & Choi, 2008; Osterberg & Blaschke, 2005; Weingart et al., 2008; WHO, 2003 .
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AdvancedPractitioner.com side effect, hand-foot syndrome, is more likely to occur with capecitabine than with bolus IV 5-FU (Twelves et al., 2005) . Prescriptions for oral anticancer agents can be filled in a variety of ways, contributing to safety concerns about access, refills, drug-drug interactions, and management of dose-limiting side effects (see Table 2 ). Patients may be hesitant about using a specialty pharmacy, preferring to continue using a familiar local retail pharmacy. However, certain cancer medications with stringent dispensing rules, such as thalidomide (Thalomid) or lenalidomide (Revlimid), must be filled through pharmaceutical access programs, which generally use specialty pharmacies.
Compared with generic IV chemotherapy agents and oral agents available in the early 1990s, newer cancer drugs are considerably more expensive. The estimated annual cost of imatinib for patients with chronic myelogenous leukemia ranges from $29,000 to $57,000 (Weingart et al., 2008) . Unfortunately, not every patient with cancer has comprehensive pharmaceutical insurance benefits.
Since cancer is primarily a disease of aging, many patients have coverage through Medicare, the federal entitlement program. Historically, Medicare only paid for treatments that were administered parenterally in a medical facility. However, in 1993, Medicare expanded coverage to include oral chemotherapy agents that have an IV equivalent, such as cyclophosphamide or etoposide. In 1999, Medicare expanded coverage to include prodrugs, such as capecitabine and temozolomide, because these drugs are metabolized into an active agent that has an IV equivalent (Bedell, 2003) A major health-care reform bill, the Reconciliation Act of 2010, was signed into law in March 2010. This act gradually reduces the amount that Medicare Part D beneficiaries will pay out-ofpocket for prescription medications. At this writing, the exact amounts remain unclear because amendments to the bill are anticipated. Information on the status of the provisions of the Reconciliation Act of 2010 can be found at http://www. healthreform.gov/
Models for Patient Motivation
Counseling patients to optimize adherence to oral therapies for cancer is not a new nursing intervention. Oncology nurses have been supporting patients on oral hormonal therapies for breast cancer and oral myelosuppressive agents for control of hematologic malignancies for many years. What have been lacking are models and theories of how individuals decide on and maintain beliefs about their health care and implement changes to improve health-care behaviors. Models that may be applicable to the investigation of adherence to cancer therapies include the Health Belief Model (HBM), Self-Regulation Theory (SRT), and the principles of educator Paolo Freire. None of these models has been validated in studies of adherence to oral anticancer therapies.
HEALTH BELIEF MODEL
The HBM has been used in preventive medicine to evaluate the likelihood that an individual will alter his or her lifestyle to effect a positive change in health. The HBM relates patients' perceptions of the seriousness of illness and efficacy of treatment with adherence to the prescribed therapy. A particular health behavior is adopted only if individuals regard themselves as susceptible to a condition they perceive to be serious; if they believe that their actions will either reduce the susceptibility to or severity of the condition; and if the perceived benefits of their actions outweigh the perceived barriers to performing the action (Becker, 1985) .
Both prospective and retrospective studies support the predictive value of the HBM, although some studies have found no association between health beliefs and adherence behavior (Janz, Champion, & Strecher, 2002; Poss, 2001) . Lifestyle demands of employment and family as well as lack of family and friend support systems can interfere with even the best plans for adherence. Patients with metastatic disease who realize that they will continue some type of treatment for the remainder of their lives may perceive the risks of nonadherence as less serious compared with a patient on adjuvant treatment who views the regimen as a cure.
That said, the HBM may be an applicable (Moore, 2007) .
SELF-REGULATION THEORY
Self-Regulation Theory (SRT) addresses patient coping with health-care experiences. Patients are responsible for coping with the experience, including making decisions about the type of treatment, complying with treatment regimens, providing self-care, and dealing with all aspects of the experience. SRT is based on the assumption that care providers accept patients as active participants in the health-care process. Effective use of SRT in clinical practice requires that health-care providers value patients' participation and practice in a way that fosters the participation in a beneficial manner .
SRT consists of three stages: (1) the patient deliberately monitors his or her behavior and evaluates how this behavior is affecting the current health situation; (2) if the desired result is not realized, the patient must decide upon an action plan for resolving the health issue and make changes to personal behavior; and (3) if the desired effect is realized, the patient reinforces the effect by continuing the behavior (Baumeister & Vohs, 2004; Hall & Fong, 2007; . Patient education following the SRT model will help the patient modify behavior through internal motivation as opposed to external motivation from the health-care provider (Baumeister & Vohs, 2004) .
SRT has been widely used in mental health settings and, in oncology, for patients undergoing radiation therapy and coping with chronic illness (Johnson, 1999; . Johnson, Fieler, Wlasowicz, and colleagues tested the hypothesis that preparatory informational interventions based on SRT delivered to patients receiving radiation therapy (N = 226) by staff nurses would reduce disruption in patients' usual life activities and have a positive effect on the moods of patients who tended to have pessimistic expectations about outcomes. The patients who received the theory-based nursing care had a 31% to 60% decrease in disruption in their usual life activities during and following radiation therapy .
FREIRIAN PRINCIPLES
Most interventions to promote medication adherence are based on psychological theories of individual behavior. A socially based adherence intervention that is guided by the educational principles of Paolo Freire (1986) asserts that adherence is influenced by the patient's social context and attempts to improve adherence through the identification of social constraints on adherence behavior (Williams et al., 2005) . Using a process of dialogue and problemsolving and working with a nurse educator, patients are encouraged to change their social environment to support their desire to achieve high levels of medication adherence. The goal of the intervention is to facilitate a self-directed process by which patients identify individual and social factors that influence their success in adherence to medication regimens and that, when recognized, can lead to more effective self-management of medication.
The Freirian educational process involves three stages: listening, participatory dialogue, and action (Freire, 1986) . Nurses who acknowledge the Freirian principle that learning is mutual and occurs through dialogue will establish the foundation for a positive and productive patientnurse relationship (Williams et al., 2005) . Used most commonly in the HIV setting, the Freirian approach may be most useful in oncology when social barriers are keeping cancer patients from achieving optimal adherence.
Facilitating Change TRANSTHEORETICAL MODEL OF CHANGE
The Transtheoretical Model of Change (TMC) is a model of intentional change that focuses on the patient's decision-making. Other approaches to health promotion have focused primarily on external social or biologic influences on behavior. In smoking cessation education, for example, a social factor with an impact on smoking behavior is peer influence, and a biologic influence is nicotine receptor activity. Within the context of the TMC, these are viewed as external influences affecting the individual. The model involves emotions, cognition, and behavior, relying heavily on self-report (Velicer, Prochaska, Fava, Norman, & Redding, 1998) .
The TMC breaks down the concept of readiness to change into discrete stages that range from lack of personal awareness for the need for change to maintaining change once it is made and stabilized. One implication of this model is that for each stage, certain helping behaviors are par-
ticularly constructive (see Table 3 ). Change implies phenomena occurring over time; the stage concept is the key organizing construct of TMC and is important because it represents a temporal dimension (Prochaska & Velicer, 1997; Prochaska, Redding & Evers, 2002; Velicer et al., 1998) .
MOTIVATIONAL INTERVIEWING
Motivation is a fundamental aspect of change. An individual must be ready, willing, and able to change. Motivational interviewing (MI) is differentiated from traditional nurse counseling by encouraging patients and health-care providers to examine health-care events together. Traditional patient education approaches have focused on the professional's assessment and resolution of the problem. MI offers a shift in focus to the patient's perception of the problem, encouraging the patient to find the solution. This method is directive and client-centered, and it helps patients explore and resolve their ambivalence about making changes in their behavior.
MI encourages health-care providers to explore a patient's understanding and concerns and to determine his or her readiness for change. It is a process that is useful for people who are in the early stages of change (Calhoun & Admire, 2005; Levensky, Forcehimes, O'Donohue, & Beitz, 2007; Possidente, Bucci, & McClain, 2005) . The fundamental premise of MI is that a patient's ambivalence about change can negatively affect motivation and readiness to alter behavior (Miller & Rollnick, 1991; Rollnick, Miller, & Butler, 2008) . Helping patients recognize a dissonance between their goals and behaviors can be a springboard for change (Prochaska, Redding, & Evers, 2002; Zimmerman, Olsen, & Bosworth, 2000) .
MI was developed to help counsel patients Note: Based on data from Prochaska et al., 2002; Prochaska & Velicer, 1997; Velicer et al., 1998; Zimmerman et al., 2000. with addictive behaviors such as alcohol abuse (Miller & Rollnick, 1991) and has not been validated in oncology patient care. However, the underlying principles of this patient-centered approach to minimize resistance to change (Miller & Rollnick, 1991; Rollnick, Miller, & Butler, 2008) lend themselves to counseling patients with cancer who seem unable to maintain optimal adherence to therapy. MI relies heavily on empathy and listening in a supportive, reflective manner, demonstrating that the health-care provider understands the patient's Levensky et al., 2007; Miller & Rollnick, 1991; Possidente et al., 2005; Rollnick, Miller, & Butler, 2008 .
AdvancedPractitioner.com Vol 1  No 3  Sep/Oct 2010 concerns and feelings. Questions such as, "How can I help you?"; "What do you need to know about ______?"; and "What does this choice mean for your future?" can encourage nonadherent patients to think about the processes that are interfering with adherence to therapy. Table 4 lists five basic MI techniques, and Table 5 provides a comparison between traditional nurse counseling and MI.
Implications for Nursing Practice
As oral therapies for cancer increase in availability and utilization, nurses in clinical practice are addressing patient education and safety issues by forming task force groups to develop policies, procedures, and patient information (Kelby, 2008) . Although policies and procedures for IV chemotherapy and biologic therapy administration are in place in most cancer centers, policies and procedures for oral therapy education, support, and patient management seem to be lagging behind.
Advanced practice oncology nurses can assume leadership roles on institutional committees to research and develop policies and procedures, and work with pharmacists, oncologists, and institutional administrators to provide evidencebased guidelines for practice. Oncology nurse researchers need to validate existing patient education and motivation models such as the HBM, SRT, TMC, Freierian principles, and MI as tools for optimizing patient experiences and outcomes with the use of oral therapy for cancer.
